ArticleGE Portuguese journal of gastroenterology
Olmesartan-Induced Enteropathy: An Unusual Cause of Villous Atrophy.
Article in GE Portuguese journal of gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Non-Celiac Villous Atrophy-A Problem Still Underestimated.Life (Basel, Switzerland) · 2025Review
- Olmesartan-Induced Enteropathy: A Rare Case of Chronic Diarrhea.Case reports in medicine · 2024Article
- Severe spruelike enteropathy and collagenous colitis caused by olmesartan.BMC gastroenterology · 2021Article
- Article
- Association of sprue-like enteropathy and angiotensin receptor-1 antagonists.Wiener klinische Wochenschrift · 2019Review
- Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue-like enteropathy: a systematic review.Gastroenterology report · 2019Review
- Olmesartan Associated Enteropathy: A Rare Underdiagnosed Cause of Diarrhea and Weight Loss.The American journal of case reports · 2019Article
- Rare Case of Olmesartan Induced Enteropathy.Spartan medical research journal · 2017Article
- Sprue-Like Enteropathy and Liver Injury: A Rare Emerging Association with Olmesartan.Journal of investigative medicine high impact case reportsArticle
- Sprue-Like Enteropathy Associated With Olmesartan: A New Kid on the Enteropathy Block.GE Portuguese journal of gastroenterologyArticle
- Sprue-Like Enteropathy Associated with Olmesartan: An Unrecognized Emerging Drug-Induced Enteropathy?GE Portuguese journal of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of a 63-year-old-man presenting with chronic diarrhea and weight loss while on olmesartan treatment for hypertension. Investigation showed multiple nutritional deficiencies associated with diffuse intestinal villous atrophy. Serologies for celiac disease were negative and other causes of villous atrophy were excluded. Olmesartan as a precipitant agent was suspected and withdrawn. Clinical improvement occurred in days with no need for other therapeutic measures. Follow-up at three months showed clinical remission and almost complete recovery of intestinal atrophy. Olmesartan is an angiotensin receptor blocker commonly prescribed for the management of hypertension. Spruelike enteropathy associated with this drug is a recently described entity with few cases reported. It presents with chronic diarrhea and intestinal villous atrophy and should be included in its differential diagnosis. This case intends to alert clinicians for the possibility of this event in a patient on treatment with this drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.